| References |
| 1 |
Lansoprazole was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
|
| 2 |
Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol. 1995 Feb;47(2):410-8.
|
| 3 |
Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther. 1996 May;277(2):805-16.
|
| 4 |
Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
|
| 5 |
An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes. Chem Biol Interact. 1998 Jul 3;114(1-2):1-13.
|
| 6 |
Identification of the human P450 enzymes involved in lansoprazole metabolism J Pharmacol Exp Ther. 1996 May;277(2):805-16.
|
| 7 |
Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol. 2005 Mar;59(3):302-9.
|
| 8 |
The gastric H,K-ATPase blocker lansoprazole is an inhibitor of chloride channels
|
| 9 |
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1725
|
